We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+31.46%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$91.5M
AUM Growth
+$23.2M
Cap. Flow
+$1.78M
Cap. Flow %
1.95%
Top 10 Hldgs %
59.03%
Holding
57
New
10
Increased
4
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
STXS icon
Stereotaxis
STXS
+$4.59M
2
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.74M
3
PLX icon
Protalix BioTherapeutics
PLX
+$1.59M
4
HSTO
Histogen Inc. Common Stock
HSTO
+$1.07M
5
KBIO
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
+$969K

Top Sells

Rank Stock Value
1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$2.52M
2
DYAX
DYAX CORPORATION
DYAX
+$2.28M
3
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$821K
4
BEAT
BioTelemetry, Inc.
BEAT
+$734K
5
INFU icon
InfuSystem Holdings
INFU
+$707K

Sector Composition

Rank Sector Weight
1 Healthcare 60.11%
2 Financials 1.25%
3 Communication Services 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
26
Johnson & Johnson
JNJ
$640B
$815K 0.89%
9,400
– –
CUTR
27
DELISTED
Cutera, Inc.
CUTR
$789K 0.86%
88,694
– –
ELOS
28
DELISTED
Syneron Medical Ltd
ELOS
$784K 0.86%
90,947
– –
KERX
29
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$748K 0.82%
74,100
-2,900
-4% -$25.8K
DSCI
30
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$706K 0.77%
57,009
– –
MACK
31
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$687K 0.75%
+23,025
New +$806K
EXAC
32
DELISTED
Exactech Inc
EXAC
$678K 0.74%
33,636
– –
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$663K 0.72%
9,598
-402
-4% -$19.8K
NVAX icon
34
Novavax
NVAX
$1.21B
$662K 0.72%
+10,500
New +$591K
SRGA
35
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$625K 0.68%
5,569
– –
DYAX
36
DELISTED
DYAX CORPORATION
DYAX
$518K 0.57%
75,500
-502,881
-87% -$2.28M
BAXS
37
DELISTED
BAXANO SURGICAL INC COM STK (DE)
BAXS
$468K 0.51%
336,351
– –
MASI
38
DELISTED
Masimo
MASI
$466K 0.51%
17,500
– –
TGTX icon
39
TG Therapeutics
TGTX
$8.19B
$378K 0.41%
+75,000
New +$459K
ACHN
40
DELISTED
Achillion Pharmaceuticals
ACHN
$368K 0.4%
121,800
– –
TGX
41
DELISTED
THERAGENICS CORP
TGX
$350K 0.38%
160,719
– –
ACGN
42
DELISTED
Aceragen Inc
ACGN
$348K 0.38%
+1,472
New +$295K
GRMH
43
DELISTED
GRAYMARK HEALTHCARE INC COM STK NEW (OK)
GRMH
$284K 0.31%
693,027
– –
PTN
44
Palatin Technologies
PTN
$14.4M
$258K 0.28%
300
-112
-27% -$93.2K
BIOL
45
DELISTED
Biolase, Inc.
BIOL
$213K 0.23%
+9
New +$290K
TNXP icon
46
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
ADAT
47
DELISTED
AUTHENTIDATE HOLDING CORP COM STK (DE)
ADAT
$126K 0.14%
15,785
– –
OCRX
48
DELISTED
Ocera Therapeutics, Inc.
OCRX
$67K 0.07%
+7,894
New +$63.6K
BGMS
49
Bio Green Med Solution Inc
BGMS
$4.86M
– –
0
– -$131K
INFU icon
50
InfuSystem Holdings
INFU
$197M
– –
-474,484
Closed -$707K
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, DAFNA Capital Management held 57 positions worth $91.5M, up 34% from $68.3M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

DAFNA Capital Management's Q3 2013 filing shows 10 new, 4 increased, 9 reduced and 4 closed positions. Its largest new stake was Ampio Pharmaceuticals Inc.: 1,419 shares worth $3.19M. The largest sale was Novadaq Technologies Inc., an estimated $2.52M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Financials and Communication Services.

  • DAFNA Capital Management's largest Q3 2013 buy was Ampio Pharmaceuticals Inc.: 1,419 shares worth $3.19M.
  • DAFNA Capital Management added most to Stereotaxis in Q3 2013, an estimated $4.59M increase.
  • DAFNA Capital Management's biggest Q3 2013 reduction was Novadaq Technologies Inc., cutting an estimated $2.52M.
  • DAFNA Capital Management fully exited InfuSystem Holdings in Q3 2013, selling an estimated $707K.
  • DAFNA Capital Management's ten largest holdings make up 59% of its $91.5M portfolio in Q3 2013.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q3 2013.
  • DAFNA Capital Management's portfolio value rose 34% quarter-over-quarter to $91.5M.

Based on DAFNA Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.